Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
318.09B
Market cap318.09B
Price-Earnings ratio
16.25
Price-Earnings ratio16.25
Dividend yield
2.77%
Dividend yield2.77%
Average volume
14.35M
Average volume14.35M
High today
$122.43
High today$122.43
Low today
$117.99
Low today$117.99
Open price
$118.31
Open price$118.31
Volume
7.96M
Volume7.96M
52 Week high
$122.43
52 Week high$122.43
52 Week low
$73.31
52 Week low$73.31

Stock Snapshot

With a market cap of 318.09B, Merck(MRK) trades at $122.00. The stock has a price-to-earnings ratio of 16.25 and currently yields dividends of 2.8%.

As of 2026-02-05, Merck(MRK) stock has fluctuated between $117.99 and $122.43. The current price stands at $122.00, placing the stock +3.4% above today's low and -0.4% off the high.

The Merck(MRK)'s current trading volume is 7.96M, compared to an average daily volume of 14.35M.

In the last year, Merck(MRK) shares hit a 52-week high of $122.43 and a 52-week low of $73.31.

In the last year, Merck(MRK) shares hit a 52-week high of $122.43 and a 52-week low of $73.31.

MRK News

TipRanks 3h
Merck announces Health Canada approval of Enflonsia for prevention of RSV

Merck (MRK) announced that Health Canada has approved Enflonsia for the prevention of respiratory syncytial virus lower respiratory tract disease in neonates an...

TipRanks 1d
Merck price target raised to $133 from $120 at Goldman Sachs

Goldman Sachs analyst Asad Haider raised the firm’s price target on Merck (MRK) to $133 from $120 and keeps a Buy rating on the shares. Merck shares rose 2.2% d...

Nasdaq 1d
Merck Reaches Analyst Target Price

In recent trading, shares of Merck & Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $92.53, changing hands for $93.13/shar...

Merck Reaches Analyst Target Price

Analyst ratings

55%

of 29 ratings
Buy
55.2%
Hold
44.8%
Sell
0%

More MRK News

TipRanks 1d
Merck price target raised to $100 from $95 at Bernstein

Bernstein raised the firm’s price target on Merck (MRK) to $100 from $95 and keeps a Market Perform rating on the shares. The firm notes Merck reported Q4 earni...

TipRanks 2d
Hold Steady on Merck: Solid Keytruda Base but Pipeline Uncertainty Keeps Upside Limited

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Merck & Company yesterday and set a price target of $109.00. Claim 50% Off TipRanks Premium Unl...

TipRanks 2d
Merck Earnings Call Balances Pressure and Pipeline

Merck & Company ((MRK)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data...

TipRanks 2d
Merck CEO: Our transformation is underway

In an interview on CNBC’s Mad Money, Robert Davis said Merck (MRK) is starting to see new launches driving growth. The company sees $70B in commercial opportuni...

Simply Wall St 2d
Is Merck Still Attractively Priced After Recent Pipeline And Partnership Updates

If you are wondering whether Merck's current share price reflects its true worth, this article walks through what the numbers are actually saying about the stoc...

Is Merck Still Attractively Priced After Recent Pipeline And Partnership Updates
TipRanks 2d
MRK Earnings: Merck Stock Slides Despite Q4 Beats

Merck (MRK) stock fell on Tuesday after the healthcare company announced earnings results for the fourth quarter of 2025. In this report, the company posted adj...

MarketWatch 2d
Merck’s outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Keytruda Qlex is a subcutaneous formation of Merck’s cancer drug. It had $40 million in sales in 2025. Merck revealed on Tuesday a lower-than-expected outlook...

Merck’s outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.